SCHEMBL2749290

SCHEMBL2749290

COC(OC)C(=O)NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MLYCD O95822 1/20 0.55
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ PLA2G1B P04054 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ ATG4B Q9Y4P1 1/20 0.54
▸ MAPK14 Q16539 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ NPC1 O15118 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ POLB P06746 2/20 0.51
▸ USP2 O75604 1/20 0.51
▸ PTPN7 P35236 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13103578 0.85 MLYCD (0.59) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL3363791 0.83 MLYCD (0.52) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL3363787 0.83 MLYCD (0.52) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL2748159 0.83 LSS (0.51) MAPK14PPARA
SCHEMBL3882782 0.82 MLYCD (0.56) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL6173159 0.82 HTR2A (0.57) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL2750089 0.82 ANPEP (0.53) RAB9APOLBPTPN7DUSP3
SCHEMBL2747972 0.82 MAPK14 (0.57) MEN1KMT2AMAPK14POLBPPARA
SCHEMBL5016361 0.81 MLYCD (0.55) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL12310890 0.80 HTR2A (0.55) MLYCDMEN1KMT2APLA2G1BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 — — US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 — — EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 — — WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MLYCD 2430/4885MEN1 511/4885KMT2A 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback